In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3738-3747

  Procissi, Daniel ^a,c   Claus, Filip ^a   Burgman, Paul ^a   Koziorowski, Jacek ^a   Chapman, J Donald ^b   Thakur, Sunitha B ^a   Matei, Cornelia ^a   Ling, C Clifton ^a   Koutcher, Jason A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CRM Consulting Services   (Canada)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 NITRO ALPHA [(2,2,2 TRIFLUOROETHOXY)METHYL]IMIDAZOLE 1 ETHANOL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 1 (2 NITRO 1 IMIDAZOYL) 3 (2,2,2 TRIFLUOROETHOXY) 2 PROPANOL; 1-(2-NITRO-1-IMIDAZOYL)-3-(2,2,2-TRIFLUOROETHOXY)-2-PROPANOL; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; MISONIDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER DIAGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; EX VIVO STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXYGEN AFFINITY; PRIORITY JOURNAL; PROSTATE TUMOR; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SOLID TUMOR; TUMOR CELL; VISIBILITY; ANIMAL; CELL HYPOXIA; EXPERIMENTAL NEOPLASM; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ANIMALS; CELL HYPOXIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLUORINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MISONIDAZOLE; NEOPLASMS, EXPERIMENTAL;

EID: 34250733045     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1563     Document Type: Article

References (49)

1. 19F Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 1998;42:701-4.
2. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
3. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
4. 2 tension measurements. Cancer Res 1991;51:6098-102.
5. Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1994;30:635-42.
6. Brizel DM, Scully SP, Harrelson J, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
7. Brizel DM, Sibley GS, Harrelson, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
8. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-56.
9. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med 2001;31:321-9.
10. Kedderris GL, Miwa GT. The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab Rev 1988;19:33-62.
11. Edwards DI. Nitroimidazole drugs - action and resistance mechanism. J Antimicrob Chemother 1993;31:9-20.
12. Chapman JD. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother Oncol 1991;20 Suppl 1:13-9.
13. Hodgkiss RI. Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. Anticancer Drug Des 1998;13:687.
14. 19F: a versatile reporter for non-invasive physiology and pharmacology using magnetic resonance. Curr Med Chem 2005;12:819-48.
15. 19F spin relaxation in index finger bones. Magn Reson Med 1990;13:358.
16. 19F magnetic resonance spectroscopy in vivo. Int J Radiat Oncol Biol Phys 1989;16:925.
17. 19F nuclear magnetic resonance at 2.35T. Int J Radiat Oncol Biol Phys 1986;12:1243.
18. Aboagye EO, Maxwell RJ, Kelson AB, et al. Preclinical evaluation of the fluorinated 2-nitroimidazole acetamide (SR4554) as a probe for measurement of tumor hypoxia. Cancer Res 1997;57:3314-8.
19. Seddon BM, Maxwell RJ, Honess DJ, Grimshaw FR, Tozer GM, Workman P. Validation of the fluorinated 2-nitroimidazole SR-4554 as a noninvasive hypoxia marker detected by magnetic resonance spectroscopy. Clin Cancer Res 2002;8:2323-35.
20. Bovey FA. Nuclear magnetic resonance spectroscopy. San Diego (CA): Academic Press; 1988.
21. 19F magnetic resonance method for measuring oxygen deficiency in tumours. Magn Reson Med 1991;22:451-66.
22. 19F MR EPI and frequency domain NIR spectroscopy. Adv Exp Med Bio 2003;530:225-36.
23. Zhao D, Constantinescu A, Chang CH, Hahn EW, Mason RP. Correlation of tumor oxygen dynamics with radiation response in dunning prostate R3327-HI tumor. Radiat Res 2003;159:621-31.
24. 19F inversion-recovery echo-planar imaging of perfluoro-15-crown-5- ether. Magn Reson Med 1994;32:88-97.
25. Sotak CH, Hees P, Huang HN, Hung MH, Krespan CG, Raynolds S. A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy. Magn Reson Med 1994;29:188-95.
26. Chapman JD, Lee J, Meeker BE. Keynote Address: Cellular reduction of nitroimidazole drugs: potential for selective chemotherapy and diagnosis of hypoxic cells. Int J Radiat Oncol Biol Phys 1989;16:911-7.
27. Burgman P, Odonoghue JA, Humm JL, Ling CC. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001;42:170-5.
28. 31P nuclear magnetic resonance spectroscopy. Cancer Res 1994;54:4885.
29. 2) using the Oxy-Lite system in R3327-AT tumors under isoflurane anesthesia. Radiat Res 2006;166:512-8.
30. Fukushima E, Roeder SBW. Experimental pulse NMR: a nuts and bolts approach. Reading (MA): Perseus Books Publishing; 1981. p.172-3.
31. Mareci TH, Brooker HR. Essential considerations for spectral localization using indirect gradient encoding of spatial information. J Magn Reson 1991;92:229.
32. Pohmann R, Von Kienlin M. Accurate phosphorus metabolite images of the human heart by 3D acquisition-weighted CSI. Magn Reson Med 2001;45:817-26.
33. Taylor RJ. An Introduction to error analysis: the study of uncertainty in physical measurements. 2nd ed. Mill Valley (CA): University Science Books; 1982.
34. Oregioni A, Walker-Samuel S, Darcy J, et al. Use of dynamic contrast-enhanced MRI to predict drug uptake in patients [abstract 760]. Proc Int Soc Magn Reson Med 2006.
35. Wardman P, Clarke ED. Oxygen inhibition of nitroreductase: electron transfer from nitro radical-anions to oxygen. Biochem Biophys Res Commun 1976;69:942.
36. Adams GE, Clarke ED, Gray P, et al. Structure activity relationships in the development of hypoxic cell radiosensitizers. II. Cytotoxicity and therapeutic ratio. Int J Radiat Biol 1979;359:151.
37. White RAS, Workman P, Brown L. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog-hydrophilic radiosensitizers potentially less toxic than misonidazole. Radiat Res 1980;84:542.
38. Seddon BM, Payne GS, Simmons L, et al. A phase I study of SR4554 via intravenous administration for noninvasive investigation of tumor hypoxia by magnetic resonance spectroscopy in patients with malignancy. Clin Cancer Res 2003;9:5101-12.
39. Robinson SP, Kostourou V, Troy H, Whitley GSJ, Griffiths JR. An in vivo assessment of the relationship of tumor hypoxia and angiogenesis [abstract 2182]. Proc Int Soc Magn Reson Med 2002.
40. 19F nuclear magnetic resonance methodologies for the assessment of tumour hypoxia. Philos Trans R Soc Lond B Biol Sci 2004;359:987-96.
41. Fiserova-Bergerova V. Metabolism and toxicity of 2,2,2-trifluoroethyl vinyl ether. Environ Health Perspect 1977;21:225-30.
42. 19FMRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumors. Radiother Oncol 2004;73:359-66.
43. 18F]-Fmiso PET data to analyse tumour hypoxia. Phys Med Biol 2005;50:2209-24.
44. Phillips TL, Wasserman TH, Johnson RJ, Levin VA, VanRaalte G. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037). Cancer 1981;48:1697-704.
45. Wasserman TH, Stetz J, Phillips TL. Clinical trials of misonidazole in the United States. Cancer Clin Trials 1981;4:7-16.
46. Wald LL, Moyher SE, Day MR, Nelson SJ, Vigneron DB. Proton spectroscopic imaging of the human brain using phased array detectors. Magn Reson Med 1995;34:440-5.
47. Zakian KL, Shukla-Dave A, Meyers P, et al. Identification of prognostic markers in bony sarcomas using proton decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 2003;63:9042-7.
48. Arias-Mendoza F, Payne GS, Zakian KL, et al. In vivo (31)P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed 2006;19:504-12.
49. Catana C, Wu Y, Judenhofer MS, Qi J, Pichler BJ, Cherry SR. Simultaneous acquisition of multi-slice PET and MR images: initial results with a MR-compatible PET scanner. J Nucl Med 2006;47:1968-76.